Armata Pharmaceuticals (ARMP) Convertible Debt (2023 - 2026)

Armata Pharmaceuticals (ARMP) has 4 years of Convertible Debt data on file, last reported at $254.9 million in Q1 2026.

• For the quarter ending Q1 2026, Convertible Debt changed N/A year-over-year to $254.9 million; the trailing twelve-month figure through Mar 2026 stood at $254.9 million (changed N/A YoY), and the FY2025 full-year result was $153.9 million, up 367.7% from the prior year.
• Convertible Debt climbed to $254.9 million in Q1 2026, from $153.9 million in the prior quarter.
• In the past five years, Convertible Debt ranged from a high of $254.9 million in Q1 2026 to a low of $30.0 million in Q3 2024.
• A 4-year average of $80.0 million and a median of $41.3 million in 2023 frame the typical range for Convertible Debt.
• Across the five-year window, Convertible Debt sank 43.89% in 2024 and soared 367.7% in 2025, its largest moves.
• Tracing ARMP's Convertible Debt over 4 years: stood at $58.6 million in 2023, then sank by 43.89% to $32.9 million in 2024, then soared by 367.7% to $153.9 million in 2025, then surged by 65.68% to $254.9 million in 2026.
• Business Quant data shows ARMP's Convertible Debt at $254.9 million in Q1 2026, $153.9 million in Q4 2025, and $30.0 million in Q3 2025.